Welcome to our dedicated page for Immuneering SEC filings (Ticker: IMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When Immuneering’s clinical updates, R&D spend, and licensing deals are buried in hundreds of pages, finding what matters can feel impossible. Biotech investors need to track cash runway, trial milestones, and executive moves before they move the market, yet the typical 10-K or 10-Q is written for regulatory lawyers, not portfolio managers.
Stock Titan solves that problem. Our platform delivers AI-powered summaries that make “Immuneering SEC filings explained simply.” Whether you’re scanning an Immuneering quarterly earnings report 10-Q filing, digging into an Immuneering annual report 10-K simplified, or monitoring Immuneering 8-K material events explained, we translate technical disclosures into plain English and update the page in real time as each document hits EDGAR. Custom alerts surface Immuneering Form 4 insider transactions real-time so you can react to Immuneering executive stock transactions Form 4 within minutes, while side-by-side charts provide “Immuneering earnings report filing analysis” without manual spreadsheet work.
Looking for specific details? Use our quick-links to jump straight to R&D expense tables, segment footnotes on the Disease Cancelling pipeline, or the Immuneering proxy statement executive compensation section. AI call-outs answer the exact questions investors ask—“understanding Immuneering SEC documents with AI,” “Immuneering insider trading Form 4 transactions,” or “how the latest data cut impacts valuation.” From pro-forma cash burn forecasts to clinical success probabilities, every insight is one click away, backed by full-text search across all filings. Stop wading through jargon and start making informed decisions with Stock Titan’s comprehensive, AI-driven coverage of Immuneering.
trivago N.V. (NASDAQ: TRVG) has filed a routine Form 6-K to comply with Section 13a-16/15d-16 of the Exchange Act.
The filing notifies investors that the company held its Annual General Meeting of Shareholders (AGM) on 27 June 2025. The only substantive attachment is Exhibit 99.1, which provides the detailed voting results for all resolutions presented at the meeting.
No financial statements, earnings data, strategic transactions or other material disclosures are included. As such, the document is largely administrative and is unlikely to influence the company’s valuation or near-term operating outlook.
Immuneering Corp. (IMRX) Form 4 filing: On 24 June 2025 the company reported two open-market insider purchases by Chief Scientific Officer Brett Matthew Hall.
• 20 Jun 2025 – Hall bought 7,415 Class A common shares at a weighted-average price of $2.6999.
• 23 Jun 2025 – Hall bought 6,007 Class A common shares at a weighted-average price of $2.4299, with individual trades executed between $2.4101 and $2.4299 (per footnote 1). Both transactions were coded “P,” confirming they were purchases rather than option exercises.
No derivative securities were reported in Table II. Following the purchases Hall now directly owns 359,318 Class A shares, up from 345,896 beforehand—an increase of roughly 3.9 %. The filing does not mark the Rule 10b5-1 safe-harbor box and contains no amendments or dispositions.
Immuneering Corporation (IMRX) filed a Form 4 on 24-Jun-2025 disclosing a small insider purchase. Chief Business Officer Harold E. Brakewood acquired 1,900 shares of Class A common stock on 20-Jun-2025 at an average price of $2.5285 per share, for an estimated total cost of about $4,805. Following the transaction, Brakewood’s direct beneficial ownership rose from 3,900 to 5,800 shares.
The filing reports no derivative activity and contains no other transactions or amendments. Because the share count and dollar value are modest relative to Immuneering’s public float, the transaction is considered routine and unlikely to materially affect the company’s capital structure or near-term valuation. Nevertheless, insider purchases can signal management’s confidence in the company’s prospects, which some investors view positively.
Form 4 filing overview for Immuneering Corp (IMRX): Director Peter Feinberg reported an open-market purchase of 25,000 Class A common shares on 06/18/2025 at a weighted-average price of $2.5275. The transaction was executed through multiple trades between $2.07 and $2.96.
Post-transaction ownership: Feinberg now holds 136,766 shares directly. In addition, he retains indirect ownership as general partner of three entities: 392,242 shares via PF Associates L.P., 476,615 shares via PEF LLC, and 115,441 shares via S4K Investments LLC, bringing his total reported beneficial ownership to approximately 1.12 million IMRX shares.
Key takeaways for investors:
- The filing reflects a net increase in insider holdings; no dispositions were reported.
- The purchase price is near recent trading lows, signalling potential confidence by a board member in the company’s valuation.
- No 10b5-1 plan was checked, indicating the transaction was not pre-scheduled under Rule 10b5-1.
Immuneering Corporation (Nasdaq: IMRX) filed a Rule 424(b)(5) prospectus supplement dated June 23, 2025 that updates its existing at-the-market (ATM) offering program.
Key points:
- Public float: Updated to approximately $83.1 million, calculated on 30,016,759 non-affiliate shares at $2.77 on 6/18/25.
- Because float now exceeds $75 million, IMRX is no longer subject to the sales limitation of Form S-3 General Instruction I.B.6, which had capped sales to one-third of public float over any 12-month period.
- ATM activity to-date: 6,155,556 shares sold for gross proceeds of $18.7 million.
- Remaining capacity: Company may now issue up to an additional $31.29 million of Class A common stock through Piper Sandler under the 8/10/22 Equity Distribution Agreement.
- Market context: Last reported share price on 6/20/25 was $2.56, implying potential dilution if new shares are issued near current levels.
Investors should review the “Risk Factors” section referenced in the base ATM prospectus, as the filing states that investing in IMRX shares involves a high degree of risk.
Immuneering Corporation (IMRX) – Form 4 insider transaction: On 06/18/2025, President, CEO, Director and 10% owner Benjamin J. Zeskind bought 21,000 shares of Class A common stock on the open market at a weighted-average price of $2.3878 per share (trades ranged $2.31-$2.44). The filing was signed on 06/20/2025.
Following the purchase, Zeskind directly owns 2,302,852 shares. In addition, an indirect holding of 894,927 shares is held by the Benjamin J. Zeskind 2020 Family Trust, for which his spouse serves as sole trustee. The transaction was coded “P” (open-market purchase), indicating an increase in ownership. The form does not reference any Rule 10b5-1 trading plan.
The purchase represents roughly 0.9% of Zeskind’s direct stake and signals continued insider support, but the absolute amount (≈$50 k) is modest relative to his existing 3.2 million-share economic interest.
FAQ
What is the current stock price of Immuneering (IMRX)?
What is the market cap of Immuneering (IMRX)?
What is Immuneering Corp's primary focus?
How does Immuneering utilize translational bioinformatics?
What distinguishes the Disease Cancelling Technology platform?
In which therapeutic areas does the company operate?
How does Immuneering generate revenue?
What role does computational biology play in its operations?
Who are Immuneering's typical partners or collaborators?
How does Immuneering differentiate itself from competitors?
